Advanced Charting With AI Automation

Confused by candlesticks? With automatic pattern recognition, AIME scans the chart, draws the lines, and tells you straight: bullish or bearish, while revealing the news behind every move.

Discover our new collection of lightweight essenti

Run the Backtest With AI Precision

Turn past reactions into smarter trades today. AIME digs into years of market data, grouping similar events like earnings calls or FOMC meetings, and calculates the results for you — win rates, max gains, and worst-case drawdowns. Want to test a custom strategy? Just ask Aime!

Newswire

Fast, factual, and for you. Your AI-powered real-time news engine.

Live Stream

Stay on pulse with real-time event coverage. From breaking headlines to live market reactions.

Expert Insights

Gain clear insights and fresh ideas from top analysts through deep, actionable market analysis.

Podcasts

Conversations that think — where markets meet discussion.

Market Dashboard

Your All-in-One Hub for Smarter Investing. Stay ahead with World News, Earnings, Macro Insights, and Portfolio Tracking — all in one place. Soon, get AI-powered recommendations tailored just for you!

Crypto Boom Ignites: Has the Tipping Point Arrived with Strategy soaring nearly 10%?

How should I invest in Recursion Pharmaceuticals now?

How can Nebius' low-price strategy in Europe challenge CoreWeave's AI supremacy in North America?

How to find hidden champions with continuously increasing market share in the consumer sector?

If I get my investment "trapped" in certain stock, what should I do?

The hard truths about building wealth👇 <video src="https://www.youtube.com/embed/3jwE4MmOQwY" poster="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Episode 19_da1d937b1765486394207.jpg" data="{&quot;videoUrl&quot;:&quot;https://www.youtube.com/embed/3jwE4MmOQwY&quot;,&quot;coverUrl&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Episode 19_da1d937b1765486394207.jpg&quot;}"></video>U.S. stocks ended Thursday at fresh record highs for the Dow Jones Industrial Average and S&amp;P 500, as investors rotated into banks and small caps while technology shares slipped following a sharp post-earnings selloff in Oracle. The Dow rose 646.26 points, or 1.34%, to 48,704.0, and the S&amp;P 500 added 14.31 points, or 0.21%, to finish at 6,900.99. The Nasdaq Composite fell 60.30 points, or 0.25%, closing at 23,593.9, reflecting weakness in megacap software and cloud names. The Russell 2000 advanced 1.18% to 257.82, underscoring a continued rotation into small-cap equities.Market breadth indicators showed broad participation: 60% of stocks advanced, more than 400 reached new highs, and over half traded above both their 50-day and 200-day moving averages. Volatility continued to retreat, with the CBOE VIX dropping 3.93% to 15.15—its lowest point in several weeks—as investors positioned for declining interest-rate risk.Commodities sent mixed signals. Gold futures for February delivery climbed 1.68% to $4,295.70, reflecting persistent hedging demand, while crude oil fell 1.30% to $57.70 after a day-long slide tied to softer demand expectations. Bitcoin retreated 2.46% to $91,349.20.Economic undercurrents continued to center on the consumer. According to the Bank of America Institute’s <a href="https://institute.bankofamerica.com/economic-insights/inside-consumers-wallets.html" target='__blank'>Inside Consumers&#39; Wallets</a> report published December 11, lower-income households “continue to face the highest inflation rates” and remain the most exposed to shifts in shelter and food costs. Oracle, by contrast, weighed heavily on the tech complex. <img data-json="{&quot;type&quot;:&quot;image&quot;,&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Screenshot 2025-12-11 at 3.44.17 PM_01c3cba01765487055770.png&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}]}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/Screenshot 2025-12-11 at 3.44.17 PM_01c3cba01765487055770.png" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />The Institute noted that rising rent burdens have made shelter the most persistent upward mover in consumer baskets for three consecutive years, while transportation’s wallet share has declined as gas prices moderated. The Bureau of Labor Statistics data cited in the report showed housing comprising 33% of the average consumer’s expenditures, far outweighing more discretionary categories.The report also emphasized the K-shaped divergence in spending patterns heading into 2026. Higher-income households have expanded restaurant and travel spending from 2019 levels, whereas those earning under $50,000 have cut back on dining out and clothing, reallocating more toward groceries. Bank of America internal transaction data showed that high-income groups increased their share of spending in airlines and entertainment, while lower-income groups shifted toward necessities.Corporate earnings added to Thursday’s crosscurrents. <a href="https://www.ainvest.com/news/adobe-dead-ai-surge-big-beats-bold-fy26-outlook-flip-narrative-2512/" target='__blank'>Adobe shares steadied</a> after the company delivered what AInvest called a “clean beat across revenue, EPS, ARR, and cash flow.” Fourth-quarter revenue rose 10% to $6.19 billion, subscription revenue climbed 12%, and Digital Media ARR reached $19.2 billion, up 11.5%. Investor expectations for accelerating AI monetization remain high, and the stock continues to trade near its downward trendline around $340.<visualization data='{&quot;components&quot;:[{&quot;show_type&quot;:&quot;jgyKline3&quot;,&quot;config&quot;:{&quot;codeName&quot;:&quot;name&quot;,&quot;marketTag&quot;:&quot;NYSE&quot;,&quot;variety&quot;:&quot;Stock&quot;,&quot;showBottom&quot;:true,&quot;moduleList&quot;:[&quot;MACD&quot;],&quot;maLine&quot;:[5,10,20,60]},&quot;title_config&quot;:{&quot;config&quot;:{&quot;display&quot;:true},&quot;data&quot;:{&quot;h1&quot;:&quot;Oracle Corporation (ORCL) Stock Chart&quot;}},&quot;data&quot;:{&quot;datas&quot;:[{&quot;code&quot;:&quot;ORCL&quot;,&quot;name&quot;:&quot;Oracle Corp.&quot;,&quot;market_code&quot;:&quot;169&quot;}]},&quot;uuid&quot;:&quot;0b99d0d9d6262736&quot;}],&quot;page&quot;:{&quot;layout&quot;:{&quot;layout_data&quot;:&quot;[{\&quot;showType\&quot;:\&quot;jgyKline3\&quot;,\&quot;uuid\&quot;:\&quot;0b99d0d9d6262736\&quot;}]&quot;},&quot;render_for&quot;:&quot;aigc&quot;,&quot;tracking_info&quot;:{}}}' dataurl='undefined'></visualization><a href="https://www.ainvest.com/news/oracle-promised-ai-future-wall-street-debt-spiral-2512/" target='__blank'>The company reported</a> 14% revenue growth to $16.1 billion and a staggering $523 billion AI-infrastructure backlog, yet free cash flow turned negative $10 billion amid $12 billion in capital expenditures. Concerns around Oracle’s ability to finance more than $50 billion in annual capex for FY26 overshadowed otherwise strong cloud metrics, sending the stock down roughly 11–12% toward the $200 support area.Despite those sector-specific pressures, cyclical leadership and easing volatility helped extend the market’s record-setting run. Financials and small caps, areas that tend to outperform in early-cycle or rate-cut environment, continued to gain traction, reinforcing expectations that equity strength could broaden beyond the handful of mega-cap growth names that drove returns earlier in the year.<video src="https://www.youtube.com/embed/U5GXAOrYWGE" poster="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/ARE YOU FINANCIALLY READY_ab87e46e1765487300736.jpg" data="{&quot;videoUrl&quot;:&quot;https://www.youtube.com/embed/U5GXAOrYWGE&quot;,&quot;coverUrl&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/ARE YOU FINANCIALLY READY_ab87e46e1765487300736.jpg&quot;}"></video>

us_low_importance

Stock

Volatility Metrics

crypto

Cryptocurrency

NorthAmerica

Long-Term Volatility

Prices

Futures

Market Cycles

Bitcoin

Oracle

Dow, S&P Close at Record Highs as Investors Rotate Into Cyclicals, Tech Lags on Oracle Slide

<img data-json="{&quot;id&quot;:&quot;8579b35b-7670-48bd-b8e9-ee0c21cdb157&quot;,&quot;type&quot;:&quot;image&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}],&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/ab36176d-6166-42d9-97ed-2cb9d1609207_1002466076524807303-IMG_80731_4ac3e4041765248139451.jpg&quot;}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/ab36176d-6166-42d9-97ed-2cb9d1609207_1002466076524807303-IMG_80731_4ac3e4041765248139451.jpg" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" /><ul><li>The SynCardia Total Artificial Heart (TAH) is the world&#39;s first and only commercially approved device in the US that fully replaces a failing human heart according to <a href="https://www.azbio.org/20-years-after-landmark-fda-approval-syncardia-remains-worlds-only-commercially-approved-total-artificial-heart" target='__blank'>AZBio</a> , serving as a bridge to transplant for patients with end-stage biventricular heart failure.</li></ul><ul><li>Picard Medical, Inc. (PMI), the parent company of SynCardia Systems, LLC, went public in 2025 and is pioneering next-generation innovations like the fully implantable Emperor TAH, which could expand the market by eliminating external drivers.</li><li>With heart failure affecting millions globally, the artificial heart sector holds significant growth potential, driven by technological advancements and an aging population.</li><li>Investing in PMI offers exposure to the medtech industry, but requires monitoring regulatory approvals, clinical trials, and market adoption, alongside risks like development delays and competition.</li><li>Evergreen opportunities in this field include long-term bets on biotech innovations, with historical precedents showing high returns for early investors in life-saving devices.</li></ul>The field of artificial hearts represents a pinnacle of medical innovation, blending engineering prowess with life-saving potential. At the forefront stands the SynCardia Total Artificial Heart (TAH), developed by SynCardia Systems, LLC, a subsidiary of Picard Medical, Inc. This device has transformed treatment options for patients with severe heart failure, offering a mechanical bridge to transplantation when no other alternatives exist. In this evergreen exploration, we&#39;ll delve into the technology behind the SynCardia TAH, its evolution under Picard Medical, and the broader implications for investors eyeing the burgeoning cardiac device market.A Brief History of Artificial Hearts and SynCardia&#39;s Role<img data-json="{&quot;id&quot;:&quot;3009c87a-26be-4a48-9fe8-138b4f5878d6&quot;,&quot;type&quot;:&quot;image&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}],&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/3deb2f33-736a-4b80-96a3-5939948568b8_image_5d0a4d7a1765248471892.png&quot;}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/3deb2f33-736a-4b80-96a3-5939948568b8_image_5d0a4d7a1765248471892.png" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />The quest for an artificial heart dates back to the mid-20th century, with early prototypes like the Jarvik-7 making headlines in the 1980s for their groundbreaking but limited success. SynCardia Systems, founded in 2001, built on this legacy by commercializing the temporary Total Artificial Heart (TAH-t), which received FDA approval in 2004 as a bridge-to-transplant device. Over the years, the company faced challenges, including a 2016 bankruptcy filing, after which it was acquired by Versa Capital Management. In a pivotal move, Picard Medical, Inc. became the holding company, fully owning SynCardia and steering it toward new innovations. Today, the SynCardia TAH remains the only commercially available total artificial heart approved by the FDA and Health Canada, according to the <a href="https://picardmedical.com/press_releases/syncardia-completes-first-in-vivo-implantations-of-next-generation-emperor-total-artificial-heart/" target='__blank'>official website</a> , with over 2,100 implants worldwide. Its design mimics the natural heart&#39;s function, pumping blood to sustain life in patients awaiting a donor organ.<rich-table border='1' data="{&quot;columns&quot;:[{&quot;id&quot;:&quot;7a94265f-b09c-4bad-9992-5097fff64946&quot;,&quot;width&quot;:155},{&quot;id&quot;:&quot;3d5cccf4-6bb1-4dfc-b839-a4c10a761f5a&quot;,&quot;width&quot;:106},{&quot;id&quot;:&quot;b9f40259-c092-45fb-9eae-e73800ebfa5f&quot;,&quot;width&quot;:526}],&quot;tableWidth&quot;:787,&quot;id&quot;:&quot;00299b46-2083-4f14-a14c-c3ad3cd7ada3&quot;}" ><tbody data="{&quot;id&quot;:&quot;fa4815f8-4712-450e-87c6-4ec79aaeb125&quot;}" ><tr data="{&quot;id&quot;:&quot;fc492e1c-aaef-450d-97ea-b138709b2882&quot;}"><td data="{&quot;id&quot;:&quot;566720cb-0e53-4ce7-963a-b705a7fd9255&quot;}">Milestone </td><td data="{&quot;id&quot;:&quot;94bca8fa-e1b8-4aee-b384-972cbf86e017&quot;}">Year </td><td data="{&quot;id&quot;:&quot;0162bc99-f469-4dd0-ad3e-05a72d7b2fed&quot;}">Description </td></tr><tr data="{&quot;id&quot;:&quot;254ad731-6b32-4aaf-80bf-6a9192bb7d11&quot;}"><td data="{&quot;id&quot;:&quot;e69e7266-1422-4429-a849-f0ac8cee9144&quot;}">Initial Development</td><td data="{&quot;id&quot;:&quot;48129aa0-8f09-41b4-b505-e21014ac4930&quot;}">1960s-1980s</td><td data="{&quot;id&quot;:&quot;cf95327a-5cf5-45d2-96da-1b548eb3d76a&quot;}">Early artificial heart concepts, including Jarvik-7, lay groundwork for modern devices. </td></tr><tr data="{&quot;id&quot;:&quot;8303e2d9-5011-438d-85f7-1b79184e0e41&quot;}"><td data="{&quot;id&quot;:&quot;e9f37a55-cf96-4c1e-8cfa-a94d39de9d08&quot;}">SynCardia Founding</td><td data="{&quot;id&quot;:&quot;6c7aecc7-3ff4-4690-a6dc-b53e076c5664&quot;}">2001 </td><td data="{&quot;id&quot;:&quot;3361e2e5-a24d-4e77-86b5-9598997e7c14&quot;}">Company established to commercialize TAH technology.</td></tr><tr data="{&quot;id&quot;:&quot;9c2624ca-41fb-4c3c-af85-2c78e06c1bf4&quot;}"><td data="{&quot;id&quot;:&quot;1f1a9cbb-1a7f-40cc-9df1-668e85bb9d65&quot;}">FDA Approval</td><td data="{&quot;id&quot;:&quot;7eda3446-f3fc-4df6-a2e9-c79c26ba468b&quot;}">2004</td><td data="{&quot;id&quot;:&quot;576032fd-202b-4a70-93f0-d05afed020a6&quot;}">SynCardia TAH approved as bridge-to-transplant</td></tr><tr data="{&quot;id&quot;:&quot;a91f02c3-15db-46fc-bc5a-009ced74e86e&quot;}"><td data="{&quot;id&quot;:&quot;ab25455b-d901-4403-8dff-e2bbf0dafe91&quot;}">Acquisition by Versa</td><td data="{&quot;id&quot;:&quot;8fc06900-bcb0-4957-878a-e9c551a50f29&quot;}">2016</td><td data="{&quot;id&quot;:&quot;2f9c3b52-9e34-42db-9870-a1baf13ad0b5&quot;}">Post-bankruptcy restructuring strengthens operations.</td></tr><tr data="{&quot;id&quot;:&quot;43026e60-a01e-4179-a973-64ae1ebac982&quot;}"><td data="{&quot;id&quot;:&quot;52bf75a9-7dd0-46c4-a8c0-542f9f5ec29c&quot;}">Picard Medical Ownership</td><td data="{&quot;id&quot;:&quot;d81e6cc2-b866-480c-8e38-7cf3d4573876&quot;}">2020s </td><td data="{&quot;id&quot;:&quot;60c9dac2-7ed2-4192-a442-06d796a47622&quot;}">Full integration and push toward next-gen Emperor TAH.</td></tr><tr data="{&quot;id&quot;:&quot;a1e2d333-84be-418c-8b9e-7ecdf18a4ff5&quot;}"><td data="{&quot;id&quot;:&quot;5d2cc693-099e-403a-aef6-40302ab9a449&quot;}">IPO and Public Trading</td><td data="{&quot;id&quot;:&quot;a59dc283-4c5f-4c2a-bb54-f6b09d8e8df2&quot;}">2025</td><td data="{&quot;id&quot;:&quot;eac562aa-684d-4979-bd33-f61de513a9e5&quot;}">Picard Medical goes public, raising funds for R&amp;D.</td></tr></tbody></rich-table>The Technology and Clinical ImpactAccording to <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3853833/" target='__blank'>National Institute of Health, </a>The SynCardia TAH is a pneumatic device that completely replaces both ventricles of the heart, connected to an external driver that powers its pulsatile flow. It is designed for patients with biventricular failure—where both sides of the heart are compromised—and has proven effective in stabilizing individuals until a transplant becomes available. Unlike ventricular assist devices (VADs) that support only one side, the TAH eliminates the failing heart entirely, reducing risks like blood clots from damaged tissue.Under Picard Medical&#39;s leadership, the focus has shifted to the Emperor TAH, a fully implantable version that promises greater patient mobility and quality of life by removing the need for external components. Recent in vivo implantations and presentations at conferences like ISMCS 2025 highlight its potential to expand the market. This advancement addresses limitations of the current model, positioning SynCardia as a leader in cardiac replacement therapy.Heart failure affects over 6 million Americans alone, with the global market for cardiac devices projected to grow significantly due to aging populations and rising chronic diseases. The SynCardia TAH&#39;s track record—over 20 years post-FDA approval—underscores its reliability, with ongoing R&amp;D enhancing its efficacy.Development Potential and Investment Opportunities<visualization data='{&quot;components&quot;:[{&quot;uuid&quot;:&quot;83b8ba4478495e35&quot;,&quot;config&quot;:{&quot;marketTag&quot;:&quot;AMEX&quot;,&quot;show_type_id&quot;:702,&quot;tradeClass&quot;:&quot;closed&quot;,&quot;title&quot;:&quot;KxxV2&quot;,&quot;fsType&quot;:&quot;closed&quot;,&quot;showBottom&quot;:true,&quot;showCodeContrast&quot;:false,&quot;score&quot;:20,&quot;show_type&quot;:&quot;kline3&quot;,&quot;maLine&quot;:[5,10,30,60],&quot;moduleList&quot;:[],&quot;variety&quot;:&quot;stock&quot;,&quot;scoreRuleNames&quot;:&quot;&quot;,&quot;tradeStatus&quot;:&quot;trading&quot;,&quot;codeName&quot;:&quot;Name&quot;,&quot;klineDefaultType&quot;:&quot;fs&quot;,&quot;title_config&quot;:{&quot;config&quot;:{&quot;display&quot;:true,&quot;display2&quot;:false,&quot;txt_style&quot;:0,&quot;url&quot;:&quot;&quot;},&quot;data&quot;:{&quot;h1&quot;:&quot;PMI Trend&quot;,&quot;h2&quot;:&quot;&quot;},&quot;show_type&quot;:&quot;title1&quot;}},&quot;data&quot;:{&quot;chunks_info&quot;:&quot;[]&quot;,&quot;code_count&quot;:1,&quot;columns&quot;:[{&quot;index_name&quot;:&quot;market_code&quot;,&quot;key&quot;:&quot;market_code&quot;,&quot;label&quot;:&quot;market_code&quot;,&quot;type&quot;:&quot;STR&quot;},{&quot;index_name&quot;:&quot;code&quot;,&quot;key&quot;:&quot;code&quot;,&quot;label&quot;:&quot;hq_code&quot;,&quot;source&quot;:&quot;fixed_index&quot;,&quot;type&quot;:&quot;STR&quot;},{&quot;domain&quot;:&quot;abs_xxxxxx&quot;,&quot;feKey&quot;:&quot;Ticker&quot;,&quot;index_name&quot;:&quot;Ticker&quot;,&quot;key&quot;:&quot;Ticker&quot;,&quot;label&quot;:&quot;code&quot;,&quot;origin_index&quot;:&quot;stock code&quot;,&quot;source&quot;:&quot;fixed_index&quot;,&quot;type&quot;:&quot;STR&quot;,&quot;unit&quot;:&quot;&quot;},{&quot;domain&quot;:&quot;abs_xxxxxx&quot;,&quot;feKey&quot;:&quot;Name&quot;,&quot;index_name&quot;:&quot;Name&quot;,&quot;key&quot;:&quot;Name&quot;,&quot;label&quot;:&quot;name&quot;,&quot;origin_index&quot;:&quot;stock name&quot;,&quot;source&quot;:&quot;fixed_index&quot;,&quot;type&quot;:&quot;STR&quot;,&quot;unit&quot;:&quot;&quot;},{&quot;feKey&quot;:&quot;Date&quot;,&quot;index_name&quot;:&quot;Date&quot;,&quot;key&quot;:&quot;Date&quot;,&quot;label&quot;:&quot;date&quot;,&quot;origin_index&quot;:&quot;Date&quot;,&quot;type&quot;:&quot;DATE&quot;},{&quot;domain&quot;:&quot;abs_xxxxxx&quot;,&quot;feKey&quot;:&quot;Closing Price&quot;,&quot;index_name&quot;:&quot;xxxx@Closing Price&quot;,&quot;key&quot;:&quot;Closing Price&quot;,&quot;label&quot;:&quot;NoIndent&quot;,&quot;report_type&quot;:&quot;TRADE_DAILY&quot;,&quot;source&quot;:&quot;&quot;,&quot;timestamp&quot;:&quot;&quot;,&quot;type&quot;:&quot;DOUBLE&quot;,&quot;unit&quot;:&quot;USD&quot;}],&quot;condition&quot;:&quot;[{\&quot;sonSize\&quot;:2,\&quot;opName\&quot;:\&quot;and\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;xxxx@stock code\&quot;,\&quot;indexProperties\&quot;:[\&quot;EQUAL PMI.A\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;EQUAL\&quot;:\&quot;PMI.A\&quot;},\&quot;domain\&quot;:\&quot;abs_xxxxxx\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;xxxx@Closing Price\&quot;,\&quot;indexProperties\&quot;:[\&quot;xxxxxx 20251208\&quot;,\&quot;xxxxxx 20251208\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;xxxxxx\&quot;:\&quot;20251208\&quot;,\&quot;xxxxxx\&quot;:\&quot;20251208\&quot;},\&quot;domain\&quot;:\&quot;abs_xxxxxx\&quot;,\&quot;relatedSize\&quot;:0}]&quot;,&quot;dataSize&quot;:1,&quot;datas&quot;:[{&quot;code&quot;:&quot;PMI&quot;,&quot;Ticker&quot;:&quot;PMI.A&quot;,&quot;market_code&quot;:&quot;170&quot;,&quot;Closing Price&quot;:&quot;2.87&quot;,&quot;Date&quot;:&quot;20251208&quot;,&quot;Name&quot;:&quot;Picard Medical&quot;}],&quot;meta&quot;:{&quot;extra&quot;:{}},&quot;row_count&quot;:1,&quot;status_code&quot;:0,&quot;status_msg&quot;:&quot;ok&quot;},&quot;category&quot;:&quot;generic&quot;,&quot;chart_type&quot;:&quot;&quot;,&quot;show_type&quot;:&quot;jgyKline3&quot;,&quot;title_config&quot;:{&quot;config&quot;:{&quot;display&quot;:true,&quot;display2&quot;:false,&quot;txt_style&quot;:0,&quot;url&quot;:&quot;&quot;},&quot;data&quot;:{&quot;h1&quot;:&quot;PMI Trend&quot;,&quot;h2&quot;:&quot;&quot;},&quot;show_type&quot;:&quot;title1&quot;},&quot;support_refresh&quot;:false,&quot;data_config&quot;:{&quot;data_ext_params&quot;:{},&quot;query_type&quot;:&quot;intusstock&quot;}}],&quot;global&quot;:{&quot;query_type&quot;:&quot;intusstock&quot;},&quot;page&quot;:{&quot;language&quot;:&quot;&quot;,&quot;layout&quot;:{&quot;layout_data&quot;:&quot;[{\&quot;showType\&quot;:\&quot;jgyKline3\&quot;,\&quot;uuid\&quot;:\&quot;83b8ba4478495e35\&quot;}]&quot;},&quot;render_for&quot;:&quot;aigc&quot;},&quot;query_condition&quot;:{},&quot;data_config&quot;:{&quot;data_ext_params&quot;:{},&quot;query_type&quot;:&quot;intusstock&quot;}}' dataurl='undefined'></visualization>Picard Medical&#39;s stewardship has injected fresh momentum into SynCardia, with investments funding the Emperor&#39;s development and clinical trials. As a publicly traded entity (PMI), the company offers investors direct exposure to this niche. The medtech sector, including artificial organs, is ripe for growth, with parallels to successful investments in devices like pacemakers or stents. Entry points for investors include monitoring milestones like FDA submissions for the Emperor, which could drive stock appreciation. With a market cap influenced by recent IPO proceeds of around $17-19 million, PMI represents a speculative but high-reward play in biotech. Broader trends, such as increasing demand for organ replacements amid donor shortages, bolster long-term potential.However, as with any medtech investment, patience is key—regulatory hurdles and clinical outcomes can sway valuations.FAQs for Aspiring Investors and Enthusiasts<img data-json="{&quot;id&quot;:&quot;e659ef70-eb75-49a6-b8ed-4da10926a50d&quot;,&quot;type&quot;:&quot;image&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}],&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/d0b95090-3679-4502-94eb-785a92454c90_image_e67fb0411765248500202.png&quot;}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/d0b95090-3679-4502-94eb-785a92454c90_image_e67fb0411765248500202.png" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />1. How does the SynCardia Total Artificial Heart work, and why is it a game-changer for heart failure treatment?The SynCardia TAH is a mechanical pump that replaces the heart&#39;s ventricles, powered by an external driver to circulate blood throughout the body. It&#39;s revolutionary because it serves as a complete substitute for patients with both sides of the heart failing, providing a reliable bridge until a transplant is possible, unlike partial support devices that may not suffice in severe cases. For newcomers to medtech, this means it buys critical time, improving survival rates in a condition affecting millions.2. What key factors should I consider before investing in a company like Picard Medical?Before diving in, evaluate the company&#39;s pipeline (e.g., the Emperor TAH&#39;s progress), financial health via quarterly reports, and market trends like rising heart disease prevalence. Use resources like FDA and Medical Publications for basics on biotech valuation—start by setting up free accounts and tracking PMI&#39;s news feeds for informed decisions.3. What risks should I watch for when investing in artificial heart companies like PMI?Key risks include regulatory delays (e.g., FDA approvals), competition from rivals like Carmat, and high R&amp;D costs leading to dilution. Market volatility in biotech can cause sharp drops—always assess financial health via reports from SynCardia official website. Diversify to mitigate.4. How can I identify entry points for investing in medtech stocks during market fluctuations?Watch for catalysts like positive clinical trial results or regulatory milestones, which often lead to price surges—use alerts on AInvest Newswire to notify you of PMI updates. For beginners, consider dollar-cost averaging during dips, but always review analyst ratings on sites like Reuters to avoid buying at peaks.5. What portfolio strategies work well for including innovative biotech like PMI without overexposing myself?Aim for a balanced approach: allocate 5-10% of your portfolio to high-growth biotech like PMI, paired with stable ETFs in healthcare. Track long-term trends via <a href="https://ainvest.com/news/articles/latest/" target='__blank'>AInvest articles</a> on organ tech, and rebalance quarterly— this hedges against volatility while capturing upside from breakthroughs like fully implantable hearts.

Medical Devices (Biotech)

tech

Biotech

Implantable Devices

Therapeutic Innovations

Healthcare Equipment 

Picard Medical

Revolutionizing Heart Failure Treatment: The SynCardia Total Artificial Heart and Picard Medical's Investment Potential

<img data-json="{&quot;id&quot;:&quot;c1cc5ddc-0001-45e7-85f9-09c33f5cf36f&quot;,&quot;type&quot;:&quot;image&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}],&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/a6ee0ed9-48c1-4cb3-8dce-42ac13eff60e_image_b3e11db81765499002633.png&quot;}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/a6ee0ed9-48c1-4cb3-8dce-42ac13eff60e_image_b3e11db81765499002633.png" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />Broadcom Inc. has ridden the artificial intelligence wave with gusto, positioning itself as a formidable challenger to Nvidia Corp. in the lucrative chip market. But on Thursday, the company&#39;s latest earnings report revealed the perils of sky-high investor expectations. Shares tumbled about 4% in after-hours trading, erasing earlier gains, as CEO Hock Tan&#39;s commentary on the AI backlog failed to ignite the enthusiasm Wall Street craved. Tan, the architect of Broadcom&#39;s aggressive pivot toward AI, described a $73 billion order backlog for AI products over the next six quarters—a figure he labeled a &quot;minimum&quot; amid lengthening lead times of six months to a year. Yet, for a stock that has surged 75% this year, closing at $406.37 before the report, the details felt like a letdown in an industry where billions are table stakes.<visualization data='{&quot;components&quot;:[{&quot;uuid&quot;:&quot;17380123da2c825&quot;,&quot;config&quot;:{&quot;image&quot;:&quot;https://lh-prod-mid-pub-newsf10.s3.amazonaws.com/logo/AVGO.png&quot;,&quot;marketTag&quot;:&quot;NASDAQ&quot;,&quot;show_type_id&quot;:702,&quot;tradeClass&quot;:&quot;post_market&quot;,&quot;title&quot;:&quot;KxxV2&quot;,&quot;fsType&quot;:&quot;closed&quot;,&quot;showBottom&quot;:true,&quot;showCodeContrast&quot;:false,&quot;score&quot;:20,&quot;show_type&quot;:&quot;kline3&quot;,&quot;maLine&quot;:[5,10,30,60],&quot;moduleList&quot;:[],&quot;variety&quot;:&quot;stock&quot;,&quot;scoreRuleNames&quot;:&quot;&quot;,&quot;tradeStatus&quot;:&quot;trading&quot;,&quot;codeName&quot;:&quot;Name&quot;,&quot;klineDefaultType&quot;:&quot;fs&quot;,&quot;title_config&quot;:{&quot;config&quot;:{&quot;display&quot;:true,&quot;display2&quot;:false,&quot;txt_style&quot;:0,&quot;url&quot;:&quot;&quot;},&quot;data&quot;:{&quot;h1&quot;:&quot;AVGO Trend&quot;,&quot;h2&quot;:&quot;&quot;},&quot;show_type&quot;:&quot;title1&quot;}},&quot;data&quot;:{&quot;chunks_info&quot;:&quot;[]&quot;,&quot;code_count&quot;:1,&quot;columns&quot;:[{&quot;index_name&quot;:&quot;market_code&quot;,&quot;key&quot;:&quot;market_code&quot;,&quot;label&quot;:&quot;market_code&quot;,&quot;type&quot;:&quot;STR&quot;},{&quot;index_name&quot;:&quot;code&quot;,&quot;key&quot;:&quot;code&quot;,&quot;label&quot;:&quot;hq_code&quot;,&quot;source&quot;:&quot;fixed_index&quot;,&quot;type&quot;:&quot;STR&quot;},{&quot;domain&quot;:&quot;abs_xxxxxx&quot;,&quot;feKey&quot;:&quot;Ticker&quot;,&quot;index_name&quot;:&quot;Ticker&quot;,&quot;key&quot;:&quot;Ticker&quot;,&quot;label&quot;:&quot;code&quot;,&quot;origin_index&quot;:&quot;stock code&quot;,&quot;source&quot;:&quot;fixed_index&quot;,&quot;type&quot;:&quot;STR&quot;,&quot;unit&quot;:&quot;&quot;},{&quot;domain&quot;:&quot;abs_xxxxxx&quot;,&quot;feKey&quot;:&quot;Name&quot;,&quot;index_name&quot;:&quot;Name&quot;,&quot;key&quot;:&quot;Name&quot;,&quot;label&quot;:&quot;name&quot;,&quot;origin_index&quot;:&quot;stock name&quot;,&quot;source&quot;:&quot;fixed_index&quot;,&quot;type&quot;:&quot;STR&quot;,&quot;unit&quot;:&quot;&quot;},{&quot;feKey&quot;:&quot;Date&quot;,&quot;index_name&quot;:&quot;Date&quot;,&quot;key&quot;:&quot;Date&quot;,&quot;label&quot;:&quot;date&quot;,&quot;origin_index&quot;:&quot;Date&quot;,&quot;type&quot;:&quot;DATE&quot;},{&quot;domain&quot;:&quot;abs_xxxxxx&quot;,&quot;feKey&quot;:&quot;Closing Price&quot;,&quot;index_name&quot;:&quot;xxxx@Closing Price&quot;,&quot;key&quot;:&quot;Closing Price&quot;,&quot;label&quot;:&quot;NoIndent&quot;,&quot;report_type&quot;:&quot;TRADE_DAILY&quot;,&quot;source&quot;:&quot;&quot;,&quot;timestamp&quot;:&quot;&quot;,&quot;type&quot;:&quot;DOUBLE&quot;,&quot;unit&quot;:&quot;USD&quot;}],&quot;condition&quot;:&quot;[{\&quot;sonSize\&quot;:2,\&quot;opName\&quot;:\&quot;and\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;xxxx@stock code\&quot;,\&quot;indexProperties\&quot;:[\&quot;EQUAL AVGO.O\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;EQUAL\&quot;:\&quot;AVGO.O\&quot;},\&quot;domain\&quot;:\&quot;abs_xxxxxx\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;xxxx@Closing Price\&quot;,\&quot;indexProperties\&quot;:[\&quot;xxxxxx 20251211\&quot;,\&quot;xxxxxx 20251211\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;xxxxxx\&quot;:\&quot;20251211\&quot;,\&quot;xxxxxx\&quot;:\&quot;20251211\&quot;},\&quot;domain\&quot;:\&quot;abs_xxxxxx\&quot;,\&quot;relatedSize\&quot;:0}]&quot;,&quot;dataSize&quot;:1,&quot;datas&quot;:[{&quot;code&quot;:&quot;AVGO&quot;,&quot;Ticker&quot;:&quot;AVGO.O&quot;,&quot;market_code&quot;:&quot;185&quot;,&quot;Closing Price&quot;:&quot;406.37&quot;,&quot;Date&quot;:&quot;20251211&quot;,&quot;Name&quot;:&quot;Broadcom&quot;}],&quot;meta&quot;:{&quot;extra&quot;:{}},&quot;row_count&quot;:1,&quot;status_code&quot;:0,&quot;status_msg&quot;:&quot;ok&quot;},&quot;category&quot;:&quot;generic&quot;,&quot;chart_type&quot;:&quot;&quot;,&quot;show_type&quot;:&quot;jgyKline3&quot;,&quot;title_config&quot;:{&quot;config&quot;:{&quot;display&quot;:true,&quot;display2&quot;:false,&quot;txt_style&quot;:0,&quot;url&quot;:&quot;&quot;},&quot;data&quot;:{&quot;h1&quot;:&quot;AVGO Trend&quot;,&quot;h2&quot;:&quot;&quot;},&quot;show_type&quot;:&quot;title1&quot;},&quot;support_refresh&quot;:false,&quot;data_config&quot;:{&quot;data_ext_params&quot;:{},&quot;query_type&quot;:&quot;intusstock&quot;}}],&quot;global&quot;:{&quot;query_type&quot;:&quot;intusstock&quot;},&quot;page&quot;:{&quot;language&quot;:&quot;&quot;,&quot;layout&quot;:{&quot;layout_data&quot;:&quot;[{\&quot;showType\&quot;:\&quot;jgyKline3\&quot;,\&quot;uuid\&quot;:\&quot;17380123da2c825\&quot;}]&quot;},&quot;render_for&quot;:&quot;aigc&quot;},&quot;query_condition&quot;:{},&quot;data_config&quot;:{&quot;data_ext_params&quot;:{},&quot;query_type&quot;:&quot;intusstock&quot;}}' dataurl='undefined'></visualization>The Palo Alto-based chipmaker, with its sprawling portfolio from communications silicon to networking gear and software, has thrived on the data center boom. AI models&#39; escalating complexity demands faster interconnections between chips, servers, and entire facilities—areas where Broadcom excels. Still, the post-earnings slide underscores a broader tension: as AI spending explodes, companies like Broadcom must deliver not just growth, but outsized leaps to justify their valuations.Earnings Highlights: A Solid Beat Tempered by Margin Pressures<img data-json="{&quot;id&quot;:&quot;c60590c2-984b-4a77-86ab-4b9f0b514804&quot;,&quot;type&quot;:&quot;image&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}],&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/e32c2ef6-14cb-4817-85e0-db48107c5b1a_image_63dea5721765499139187.png&quot;}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/e32c2ef6-14cb-4817-85e0-db48107c5b1a_image_63dea5721765499139187.png" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />Broadcom&#39;s fiscal fourth quarter, ending November 2, delivered results that would envy most tech peers. Revenue climbed 28% year-over-year to $18.02 billion, surpassing the $17.49 billion analysts had anticipated, per LSEG data. Adjusted earnings per share hit $1.95, beating estimates of $1.86. Net income nearly doubled, soaring 97% to $8.51 billion, or $1.74 per share, from $4.32 billion a year earlier.The semiconductor solutions segment, home to Broadcom&#39;s AI chips, grew 22% to $11.07 billion, topping StreetAccount&#39;s $10.77 billion forecast. AI chip sales within this unit jumped 74%, equating to $8.2 billion for the quarter—a testament to the company&#39;s custom accelerators and networking prowess. Meanwhile, the infrastructure software arm, bolstered by VMware acquisitions, expanded 26% to $6.94 billion, exceeding expectations.Looking ahead, Broadcom projected first-quarter revenue of about $19.1 billion, implying 28% growth and outpacing the $18.3 billion consensus. The company also sweetened its appeal to shareholders with a 10% dividend hike to 65 cents per share, payable later this month. These figures paint a picture of robust health, yet Tan&#39;s warnings about narrowing profit margins—driven by the high costs of AI product ramps—cast a shadow. &quot;It&#39;s a moving target,&quot; Tan said of the AI landscape, declining to offer a 2026 revenue forecast despite analyst prodding.AI Outlook: Doubling Down Amid Investor ScrutinyAt the heart of Broadcom&#39;s narrative is its AI trajectory, where revenue is set to double to $8.2 billion in the current quarter from a year ago. This surge stems from custom AI chips—dubbed XPUs—and semiconductors tailored for AI networking. Tan emphasized the company&#39;s role in the massive data center expansion, where its designs underpin hyperscalers&#39; ambitions.Yet, the $73 billion backlog, spanning custom chips, switches, and other AI data center components over the next 18 months, drew mixed reactions. Tan positioned it as a floor, noting that additional orders could swell the pipeline as lead times extend. &quot;We do expect much more,&quot; he assured analysts, highlighting the fluidity of demand in this nascent market.Broadcom&#39;s reluctance to pinpoint future AI sales reflects the sector&#39;s volatility. AI models are evolving rapidly, requiring ever-faster data movement—a boon for Broadcom&#39;s updated networking equipment. But with profit margins compressing under the weight of these investments, investors are left pondering the sustainability of the growth spurt.Customer Wins: From Anthropic to OpenAI, Partnerships Fuel Momentum<img data-json="{&quot;id&quot;:&quot;a9599680-b663-4e7b-a55d-2ab8e9f77466&quot;,&quot;type&quot;:&quot;image&quot;,&quot;alt&quot;:&quot;&quot;,&quot;children&quot;:[{&quot;text&quot;:&quot;&quot;}],&quot;src&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/24a1dac9-4037-4ec4-943b-8a710888d18c_image_0a15fdb51765499248420.png&quot;}" src="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/24a1dac9-4037-4ec4-943b-8a710888d18c_image_0a15fdb51765499248420.png" contentEditable="false" style="display: block; margin: 0 auto; maxWidth: 100%" />Broadcom&#39;s AI credentials shine through its marquee deals. In the fourth quarter, the company secured an $11 billion order from AI startup Anthropic PBC, following a $10 billion commitment in the third quarter. Anthropic, leveraging Google&#39;s latest Ironwood TPUs—which incorporate Broadcom designs—represents a deepening entanglement with cloud giants like Alphabet Inc.Tan also disclosed a fifth custom chip customer, unnamed but with a $1 billion order slated for delivery in late 2026. This builds on a June tally of three customers and four prospects, evolving to include a fourth mystery buyer by September. The October pact with OpenAI, the force behind ChatGPT, stands out: Broadcom will supply custom chips and networking components to power OpenAI&#39;s AI services, granting deeper market penetration.These alliances position Broadcom as a key enabler in the AI arms race. Google&#39;s TPUs, increasingly adopted as Nvidia alternatives, rely on Broadcom&#39;s innovations, while OpenAI&#39;s shift toward proprietary silicon underscores a trend among AI leaders to &quot;control their own destiny,&quot; as Tan put it. With Anthropic now identified as the prior $10 billion TPU buyer, investors gain clarity on Broadcom&#39;s expanding roster, even as some crave more specifics on deployment timelines.Challenges Ahead: Balancing Growth and ExpectationsDespite the triumphs, Broadcom operates in Nvidia&#39;s long shadow, where the latter dominates AI processors. Broadcom&#39;s custom chip unit has seen revenue climb, but the company must navigate intensifying competition and supply chain strains. Tan&#39;s performance-linked incentives—a potential 610,521 shares if AI revenue reaches $90 billion by fiscal 2030, scaling to 300% at $120 billion—align his fortunes with shareholders, yet they amplify the pressure to deliver.The margin squeeze from AI sales highlights a trade-off: explosive top-line growth at the expense of profitability. As data centers scale, Broadcom&#39;s ability to innovate in connectivity will be crucial, but any hiccup in order fulfillment could exacerbate volatility.In a year where Broadcom shares have outperformed amid AI fervor—doubling last year and up 75% in 2025—the earnings reaction serves as a reality check. Investors, primed for disappointment after a 170% rally in recent memory, are demanding proof that Broadcom&#39;s AI payoff will match the hype.Looking Forward: Can Broadcom Soldier through the Tough Time?As Hock Tan steers Broadcom through this transformative era, the company stands at a crossroads. With a fortified dividend, beating forecasts, and a swelling AI backlog, the fundamentals remain strong. Yet, the stock&#39;s dip signals that in the high-stakes AI arena, even solid progress can feel insufficient.Broadcom&#39;s partnerships with OpenAI, Anthropic, and Google position it as an indispensable player, but sustaining momentum will require navigating margin pressures and delivering on those multibillion-dollar promises. For now, Tan&#39;s cautious optimism—&quot;I&#39;d rather not give you guys any guidance&quot;—leaves room for upside, but also for skepticism. In an industry where fortunes pivot on the next breakthrough, Broadcom&#39;s journey from AI contender to leader hangs in the balance.

Negative Catalysts

Movers

Top Losers

Percentage Declines

Artificial Intelligence

Chip Stocks

Semiconductor

Broadcom

Broadcom's AI Bet Falls Short, Sending Shares Tumbling Despite Beat

<video src="https://www.youtube.com/embed/3jwE4MmOQwY" poster="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/CandPEpisode 19_638ac91b1765486153259.jpg" data="{&quot;videoUrl&quot;:&quot;https://www.youtube.com/embed/3jwE4MmOQwY&quot;,&quot;coverUrl&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/CandPEpisode 19_638ac91b1765486153259.jpg&quot;}"></video>Space has been hot for months, but 2026 is shaping up as the year it goes full mania—thanks to a potential <a href="https://www.cnbc.com/2025/12/11/musk-says-spacex-report-of-2026-ipo-is-accurate.html" target='__blank'>SpaceX IPO</a> that could raise more than $30 billion and value <a href="https://x.com/elonmusk/status/1997399963509150089?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1997399963509150089%7Ctwgr%5Eaa96d9785f5b3eb25896580b5147bbb14599dcfa%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fwww.barrons.com%2Farticles%2Fspacex-ipo-tesla-stock-8e46370f" target='__blank'>Elon Musk&#39;s</a> rocket-and-satellite empire at roughly $1.5 trillion. That would make it not only the biggest IPO in history, but also the market’s purest listed play on the commercial space economy and space-based broadband through Starlink. It’s the kind of deal that can pull capital away from everything else for a moment and then, if it trades well, pull everyone back into the broader space complex with even more enthusiasm.SpaceX has reportedly told investors it’s targeting an IPO in the second half of 2026, while also weighing a secondary sale valuing the company near $800 billion in the private market. The IPO is expected to include Starlink, reversing earlier talk of spinning it out separately. That matters: most of the bullish valuation work, like Cathie Wood’s $2.5 trillion by 2030 scenario, rests heavily on Starlink and Starshield, not just launch. With more than half of global orbital launches and millions of broadband subscribers already, SpaceX is effectively the index of “New Space.” Taking that public is a structural shift, not just another ticker.The catch, of course, is valuation and crowding. A $1.5 trillion IPO with $30 billion or more in stock for sale will demand attention and liquidity from across the market. Some investors are already worrying that such a huge deal could be a short-term drag on risk assets as portfolios sell other positions to make room. But if the stock trades well, it will likely re-rate the entire sector higher, validate business models that currently live on PowerPoints, and open the door for more follow-on offerings and new listings.For now, investors looking to front-run a SpaceX IPO have been playing the ecosystem. One of the cleanest (if imperfect) proxies has been EchoStar (SATS), which sold large blocks of spectrum (AWS-4 and H-block) to SpaceX in exchange for billions in SpaceX stock. At a recent private valuation around $400 billion, Morgan Stanley estimated that every $100 increase in SpaceX’s share price adds roughly $18 per SATS share, or about 20% to SATS equity. That leverage goes both ways, but it explains why SATS has been up several hundred percent year-to-date, and why bulls can model much higher upside if SpaceX lists at, or trades to, nosebleed levels.Another way investors have tried to game SpaceX has been <a href="https://destiny.xyz/tech100" target='__blank'>Destiny Tech 100</a> (DXYZ), a closed-end fund that holds pre-IPO stakes in high-growth private tech names including SpaceX, OpenAI, and others. In practice, DXYZ has behaved more like a meme vehicle than a sober allocation tool: it has traded at massive premiums to net asset value, ripped over 1,000% at one point, and then cratered as the premium vanished. For retail traders, it’s a cautionary reminder that “access” to unicorns via closed-end structures often comes with extreme volatility, high fees, and serious downside if sentiment turns.For investors who want space exposure without betting the farm on one company or one private-markets wrapper, the Procure Space ETF (UFO) has quietly become the sector’s benchmark. UFO has returned over 60% year-to-date, far outpacing broad equity indices, as enthusiasm has poured into satellite communications, imagery, launch providers, and defense-linked space assets. The ETF holds names like AST SpaceMobile (ASTS), Globalstar (GSAT), Planet Labs (PL), EchoStar (SATS), ViaSat (VSAT), Rocket Lab (RKLB), and traditional aerospace and defense giants (RTX, LMT, NOC), giving investors a diversified way to participate in the run-up to SpaceX’s debut without stock-picking every launch schedule and satellite constellation.The macro setup for 2026 also looks unusually supportive. The global space economy is roughly a $600 billion business today, but forecasts have it tripling to around $1.8 trillion by 2035, with communications, data, defense, and in-orbit services driving much of the growth. SpaceX’s IPO could act as a catalyst that unlocks more institutional capital for everything from satellite networks to on-orbit servicing and debris removal. At the same time, rising interest in AI and energy-intensive compute is fueling serious talk of orbital data centers, with both SpaceX and Jeff Bezos’s Blue Origin reportedly exploring ways to move compute off Earth. That shifts space from “cool rockets” to core digital infrastructure, which tends to command much higher valuation multiples.On top of that, the sector is already seeing a new wave of listings and follow-on capital raises. Smaller players like Starfighters Space are trying to bring innovative launch models (air-launch from F-104 jets) to market, while more traditional satellite operators and defense technology names lean into the space narrative to raise capital and highlight their exposure. If SpaceX does, in fact, come public in late 2026 and trades well, it could trigger a flurry of IPOs, spins, and secondary offerings across the ecosystem—exactly the environment that tends to create both outsized winners and painful value traps.Below are some of the key publicly traded names in the space complex that investors may want to watch as the SpaceX IPO story evolves:• SATS – EchoStar

EchoStar has become the purest listed derivative of SpaceX’s private valuation, thanks to its spectrum-for-equity deals that left it holding billions of dollars in SpaceX stock. Beyond the SpaceX stake, SATS owns scarce and appreciating spectrum assets that major U.S. wireless carriers are expected to covet, giving it multiple potential catalysts. The stock has already rerated sharply higher, but analysts still see upside if spectrum sales are realized at attractive prices and tax leakage is managed, and if SpaceX’s eventual IPO validates higher embedded value. The flip side is that investors are now heavily exposed to both regulatory outcomes around spectrum and the vagaries of SpaceX’s private-market pricing.• GSAT – Globalstar

Globalstar is a satellite communications company with globally harmonized spectrum in S-band, L-band, and C-band, and it is increasingly positioning itself as a partner platform for private 5G and IoT connectivity. Recent commentary highlighted its large HIBLEO-XL-1 system and the potential for a future megaconstellation built with partners rather than GSAT shouldering all the capex. Analysts see GSAT as being at a strategic inflection point, with terrestrial spectrum monetization starting to kick in thanks to new channel partners and radio access network innovations. Speculation about strategic alternatives, including possible interest from larger players like SpaceX, only adds more optionality—and more volatility.• VSAT – ViaSat

ViaSat straddles the line between traditional satellite operator and higher-growth defense technology provider, with its Defense &amp; Advanced Technologies segment increasingly viewed as the crown jewel. The company has endured a rough stretch of technical issues with its Viasat-3 satellites, but recent results and an ongoing strategic review of the defense business have reopened the sum-of-the-parts upside story. If the spin-out of its defense unit proceeds and executes well, investors could see multiple expansion as that business is valued against higher-multiple defense tech comps instead of legacy satellite peers. Risks remain around launch execution, Starlink competition, and government budget noise, but the risk/reward is becoming more interesting as the sector re-rates.• RKLB – Rocket Lab

Rocket Lab has emerged as one of the few credible non-SpaceX launch providers, focusing on small and medium payloads with its Electron rocket and developing the larger Neutron vehicle. The company has also pushed aggressively into spacecraft components and satellite buses, trying to build an integrated offering instead of being just a launch “taxi.” Shares have rallied alongside the broader space trade, helped by the prospect of rising launch demand as more constellations come online. Execution on Neutron and the economics of its manufacturing scale-up will be critical, as investors are quick to punish delays or cost overruns in a post-SPAC environment.• UFO – Procure Space ETF

UFO itself deserves a mention as a one-stop vehicle for diversified exposure to the space theme ahead of the SpaceX IPO. The ETF holds a mixture of pure-play space names and diversified defense and communications firms, using a tier-weighted methodology tied to how much revenue each company derives from space-related activities. Its strong performance and growing inflows suggest it has become the default way for many investors to express a space view without stock-specific risk. If a wave of new space listings hits in 2026, UFO is likely to be both a beneficiary and a barometer of how much capital is rotating into the theme.• DXYZ – Destiny Tech100

DXYZ is effectively a packaged bet on private tech unicorns, with SpaceX often representing a large, concentrated position in the portfolio. For investors unable to access late-stage private rounds directly, it provides a rare public-market shortcut—but at the cost of extreme volatility and the risk of paying huge premiums to underlying NAV. The fund’s wild price swings, driven as much by retail enthusiasm as by changes in private valuations, make it more of a tactical trading vehicle than a steady allocation to the space economy. Still, as SpaceX moves closer to an IPO, DXYZ’s “SpaceX factor” is likely to keep it in the crosshairs of speculative traders.SpaceX going public in 2026 will be more than just another mega-deal; it will be a referendum on the entire idea that space is shifting from “science project” to critical infrastructure for communications, defense, and AI compute. For investors, the challenge over the next year isn’t simply waiting to see the SpaceX ticker—it’s figuring out which parts of the ecosystem deserve capital now, while the launch window is still wide open.

market

Direct Listing

Buybacks

Liquidity Considerations

Volume Spikes

Directed/Private Buybacks

Institutional Participation

Top Gainers

Percentage Gains

Deals

WallStreetBets

Commercial Spaceflight

AST SpaceMobile

Viasat

Wall Street Is Bracing for the Biggest IPO in History — And It Might Reshape the Entire Space Economy

<video src="https://www.youtube.com/embed/3jwE4MmOQwY" poster="https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/CandPEpisode 19_cf97c7b91765476299422.jpg" data="{&quot;videoUrl&quot;:&quot;https://www.youtube.com/embed/3jwE4MmOQwY&quot;,&quot;coverUrl&quot;:&quot;https://cdn.ainvest.com/articles/focusnews/coverimage/content/pictures/CandPEpisode 19_cf97c7b91765476299422.jpg&quot;}"></video>Costco enters <a href="https://www.nbcnews.com/business/business-news/costco-sues-trump-tariff-refunds-rcna246860" target='__blank'>tonight&#39;s earnings release</a> with a rare combination of strong fundamentals and a strangely defensive market tone. Shares have underperformed the broader market this year—down about 3 percent versus the S&amp;P 500’s 16 percent gain—and sentiment is the most cautious analysts have seen in years. The company has already preannounced its three months of revenue, as it typically does, but that hasn’t settled nerves. Instead, investors are going into this print focused on comps, margin resilience, the lawsuit filed against the Trump administration over tariffs, and questions about whether renewal rates have finally peaked. With the stock down roughly 15 percent from February’s all-time highs and valuations still rich at ~43–45x forward earnings, expectations are both low—and strangely consequential.First, the <a href="https://finance.yahoo.com/news/costco-cost-q4-earnings-expect-030108301.html" target='__blank'>top-line backdrop</a> is already known. Costco reported Q1 net sales of $65.98 billion, almost exactly in line with consensus and well-telegraphed through its customary monthly updates. November sales came in at $23.64 billion, October at $21.75 billion, and September at roughly $26.6 billion, with U.S. comparable sales consistently running in the mid-single-digit range. Comps ex-gas and ex-FX rose +5.8 percent in November and +5.9 percent for Q1 overall, while total comps hit +6.4 percent. Categories like fresh foods and sundries held up well with MSD/HSD performance, and nonfoods remained solid thanks to jewelry, gift cards, and seasonal inventory. Truist captured the market’s thinking succinctly: business trends remain healthy, but at a ~45x multiple, investors want more than “solid.”EPS expectations sit around $4.24–$4.28, with revenue projected near $67.1 billion—an ~8 percent year-over-year increase. Analysts have nudged estimates upward over the last three months (11 upward EPS revisions vs. seven down), suggesting confidence in some degree of upside. But Costco’s stock has struggled on recent prints, and Oppenheimer notes that sentiment is unusually negative—partly because the shares pulled back after reaching stretched valuations, and partly because investors fear margin pressures from tariffs and mix shifts.That brings us to one of the most unusual storylines heading into an earnings report: Costco’s lawsuit against the Trump administration over tariffs imposed via the International Emergency Economic Powers Act (IEEPA). The company is seeking a full refund of duties paid under the law, arguing that the act does not authorize the president to impose tariffs. With the Supreme Court now reviewing the legality of Trump’s tariff framework—and both conservative and liberal justices expressing skepticism about the government’s defense—this has become a major swing factor for Costco’s future cost structure.Costco hasn’t disclosed exactly how much it paid in tariffs, but U.S. importers overall have paid nearly $90 billion under IEEPA-based duties. The company previously noted that about one-third of its U.S. products are imported, with China representing about 8 percent of total U.S. sales. CFO Gary Millerchip has repeatedly stated that Costco attempted to maintain member value by not passing along tariff-related increases on key staples—fresh produce being the most cited example—meaning Costco has been absorbing margin pressure for years. If the Court strikes down the tariffs, Costco could receive a sizable refund, and more importantly, a structural margin boost. If the Court upholds them, management must continue mitigating costs through supplier negotiations, country-of-origin shifts, and global consolidation of buying power.Investors will be laser-focused on tonight’s commentary around this case—not because Costco’s near-term earnings hinge on it, but because it influences whether a special dividend or stock split becomes more likely. OPCO flagged this dynamic clearly: a tariff refund would free up capital and clear the way for shareholder-friendly actions, whereas prolonged uncertainty may keep management cautious.Membership dynamics are another major storyline. Renewal rates ticked down to 89.8 percent from 90.2 percent last quarter—something UBS labeled the steepest quarterly decline in 15 years. Management attributes this entirely to mix shift: online sign-ups tend to renew at lower rates. While that explanation is reasonable, investors want proof this is a temporary phenomenon. Membership fee income is one of Costco’s most predictable profit engines; any perceived instability generates outsized anxiety. Analysts expect management to reaffirm confidence that renewal rates will stabilize as digital cohorts mature, especially as auto-renew adoption rises.Beyond those headline concerns, investors are watching a handful of operational themes that may influence how the stock trades post-print:• Warehouse expansion – Costco plans to open 35 new locations in FY26 (vs. 27 in FY25), signaling continued confidence in domestic and international opportunity.

• Margin performance – Fresh food, sundries, and nonfood categories have supported steady margin gains, and analysts will be watching whether supply chain efficiencies and Kirkland Signature penetration continue to offset inflation and tariffs.

• Digitally enabled sales – Costco has shifted to reporting digitally enabled comps, reflecting a more omnichannel view. E-commerce comps were +13.6 percent last quarter, and investors want to see that hold as consumers remain budget-constrained.

• Consumer health – As a bellwether for value-seeking shoppers, Costco’s trends often front-run broader retail data. Traffic and ticket size in Q1 will be read as proxies for holiday-season health.

• Peer read-through – Walmart posted a very strong quarter, raising guidance and seeing e-commerce accelerate. Analysts view Walmart as a positive indicator for Costco demand, particularly among higher-income households trading down.Valuation also plays a role in tonight’s setup. Even after the pullback, Costco’s 43–45x forward multiple remains elevated relative to peers and the market. That high bar means “in-line” results may not be enough; investors want reaffirmed confidence in share gains, resilience in membership economics, and transparency around tariff outcomes. On the flip side, the skepticism may actually help: OPCO views expectations as unusually low, calling this one of the best risk/reward setups Costco has had in months.The preannounced sales data already shows healthy consumer demand. The core comps are solid. Membership remains robust despite mix noise. And the tariff lawsuit introduces an unconventional—but potentially powerful—new catalyst.If Costco can deliver a clean quarter, provide reassurance around renewal rates, and offer credible commentary on tariffs and margins, this could be the moment the stock resets—and possibly reclaims its leadership mantle in 2026.

politics

Call Options

us_middle_importance

Long-Term Calls

Earnings-Risk Factors

MktOptions

SEC Filings

Tariff Adjustments

Trade Policies

Policy

Economic Policy

Form 10-K

Earnings

Volatility Considerations

New Retail

Logistic

Costco Wholesale

Costco Faces Its Most Important Earnings in Years: Tariffs, Membership Risks, and a Surprise Setup

Eric Jackson's Bullish Investment Thesis Sends Nextdoor Stock Trending

Baxter International: A Value Opportunity Amidst Restructuring Efforts and Debt Debates

Venezuelan lawmakers repeal Rome statute law, clearing path to withdraw from International Criminal Court

Meta is About to Advance on "Avocada"? Zuckerberg Betting Big on the Closed-Model Future

Disney shares rise over 2% pre-market; company to invest $1B in OpenAI equity

U.S. stock index futures fall, Nasdaq 100 down 1%, Dow Jones down 0.18%, S&P 500 down 0.61%.

EM Assets Down Amid Powell Commentary and Oracle Earnings Concerns

Morgan Stanley cuts Meta target price to $750 from $820

Citi: Oil prices will likely ease further to an average of $60/bbl through 1Q’26 as stockbuilds materialize in OECD inventories

US Department of Transportation expands use of Salesforce and adds AI agents to modernize national transportation and safety

Why AMD and Alibaba Could Overtake Palantir in 2026: A Valuation and Growth Analysis

Bank of Japan reluctant to intervene on rising yields, sources say - Reuters

Lump Sum vs. Annuity: A 20-Year-Old's Lottery Choice and Its Investment Implications

Regulatory Risk and Stablecoin Innovation in Crypto: Post-Terra/Luna Implications for Institutional Trust and Asset Safety

The Do Kwon Case: A Wake-Up Call for Crypto Due Diligence and Regulatory Vigilance

Why BullZilla Outshines Solana and Meme Coins as the #1 Altcoin for 100x Gains in 2025

Bitcoin's Post-Fed Rate Cut Failure: A Cautionary Signal for Institutional-Driven Rallies?

Tenaya Therapeutics' TN-401 ARVC Gene Therapy: Interim Clinical Signals and Financial Risk Assessment

Coinbase Leans on Chainlink to Fuel Wrapped Asset Expansion Across Chains

Why Broadcom's Earnings Volatility Signals Strategic Buy Opportunities for Long-Term Investors

Natural Grocers 2025 Q4 Earnings 31.0% Net Income Growth Drives Strong Performance

Mitek Systems 2025 Q4 Earnings Revenue Beats Expectations, EPS Declines 78%

Is the Invesco Global Core Equity Fund Still a Global Growth Engine? A Sustainability Check

Strategic Positioning for Early-Stage Investment in DeFi Infrastructure: The Case of Sanctum

Ainvest Option Flow Daily Digest - 2025-09-19 

Buying Oracle Shares Won't Make You As Rich As Larry Ellison, But Not Doing So Will Surely Leave You With Regret 

Micron’s AI Memory Machine Keeps Humming—But the Tape Wants Even More

UBS Sees Tesla Exceeding 500K Q3 Deliveries, New Record Ahead

Latest

Lump Sum vs. Annuity: A 20-Year-Old's Lottery Choice and Its Investment Implications

Regulatory Risk and Stablecoin Innovation in Crypto: Post-Terra/Luna Implications for Institutional Trust and Asset Safety

The Do Kwon Case: A Wake-Up Call for Crypto Due Diligence and Regulatory Vigilance

Why BullZilla Outshines Solana and Meme Coins as the #1 Altcoin for 100x Gains in 2025

Bitcoin's Post-Fed Rate Cut Failure: A Cautionary Signal for Institutional-Driven Rallies?

Tenaya Therapeutics' TN-401 ARVC Gene Therapy: Interim Clinical Signals and Financial Risk Assessment

Coinbase Leans on Chainlink to Fuel Wrapped Asset Expansion Across Chains

Why Broadcom's Earnings Volatility Signals Strategic Buy Opportunities for Long-Term Investors

Natural Grocers 2025 Q4 Earnings 31.0% Net Income Growth Drives Strong Performance

Mitek Systems 2025 Q4 Earnings Revenue Beats Expectations, EPS Declines 78%

Is the Invesco Global Core Equity Fund Still a Global Growth Engine? A Sustainability Check

Strategic Positioning for Early-Stage Investment in DeFi Infrastructure: The Case of Sanctum

US stocks

Trending tickers

Stocks gainers

Stocks losers

Crypto

Trending cryptos

Crypto gainers

Crypto losers